Target- |
Mechanism- |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date16 Oct 2008 |
A Phase III, Randomized, Double-blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Pirfenidone in Subjects With Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
The purpose of this study is to evaluate the eEfficacy and safety of pirfenidone in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury
The purpose of this study is to assess the safety and efficacy of pirfenidone capsules to treat grade 2 or above radiation-induced lung injury patients.
100 Clinical Results associated with GNI-EPS Pharmaceuticals, inc.
0 Patents (Medical) associated with GNI-EPS Pharmaceuticals, inc.
100 Deals associated with GNI-EPS Pharmaceuticals, inc.
100 Translational Medicine associated with GNI-EPS Pharmaceuticals, inc.